ViewRay Incorporated

172 articles with ViewRay Incorporated

• ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock

  12/6/2019

  ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 47,782,500 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $149.6 million

• ViewRay Announces Pricing of Public Offering of Common Stock at $3.13 per share

  12/4/2019

  ViewRay, Inc. announced the pricing of an underwritten public offering of 41,550,000 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $130.1 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.

• ViewRay Announces Proposed Public Offering of Common Stock

  12/2/2019

  ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock.

• ViewRay Announces Collaborations with Elekta and Medtronic

  12/2/2019

  ViewRay, Inc. (Nasdaq: VRAY) announced today that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB (Nasdaq: EKTA-B.ST) ("Elekta") to advance the knowledge and use of MR-guided radiation therapy. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay

• ViewRay® to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference

  11/20/2019

  ViewRay, Inc. announced that the Company will participate in the 2019 Piper Jaffray 31st Annual Healthcare Conference in New York, New York. Scott Drake, President and CEO, will give a presentation at 1:30p.m. Eastern Time on Wednesday, December 4, 2019.

• ViewRay Reports Third Quarter 2019 Results

  11/12/2019

  ViewRay, Inc. announced financial results for the third quarter ended September 30, 2019..

• European Symposium to Advance Adoption of MRI-Guided Radiation Therapy

  10/24/2019

  Educational Event to Feature Presentations from MRIdian® Users and ESTRO Past President on the Strategic, Economic, Clinical and Technical Aspects of MRI-Guided Radiation Therapy

• ViewRay Announces Preliminary Third Quarter 2019 Results and Details of Upcoming Conference Call

  10/15/2019

  ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the third quarter 2019

• Patient Treatments with ViewRay's MRIdian Linac Begin in New England

  10/7/2019

  Joint Cancer Program in Boston First in New England to Offer MRI-Guided Radiation Therapy

• VRAY NOTICE: ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against ViewRay, Inc.

  9/19/2019

  Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ViewRay, Inc. (NASDAQ: VRAY) from March 15, 2019 through August 8, 2019, inclusive (the "Class Period")

• Penn State Health Enters into Master Purchase Agreement with ViewRay for MRIdian® Systems

  9/16/2019

  ViewRay, Inc. (NASDAQ: VRAY) announced today that Penn State Health has entered into a master agreement for the purchase of up to four MRIdian systems, placing an order for its first system today

• ViewRay Announces Collaboration with Stanford Health Care

  9/12/2019

  Stanford Health Care to Acquire a ViewRay MRIdian System

• Leading Radiation Oncology Meeting to Feature Unique Capabilities and Compelling Patient Outcomes with ViewRay's MRIdian

  9/10/2019

  Clinicians from 17 Hospitals Worldwide to Present Clinical Experience with MRIdian MRI-Guided Radiation Therapy at ASTRO

• ViewRay to Host Investor Meeting at 2019 ASTRO Annual Meeting in Chicago

  8/27/2019

  ViewRay, Inc. announced that the Company will host a physician-led informational discussion for investors and analysts during the 2019 American Society of Radiation Oncology Annual Meeting in Chicago.

• ViewRay Announces Results of the First Prospective Clinical Trial on MR-guided Radiation Treatment for Prostate Cancer Without Implanted Markers

  8/19/2019

  ViewRay, Inc. (Nasdaq: VRAY) announced today the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer.

• ViewRay® to Participate in Upcoming Investor Conferences

  8/15/2019

  ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in two upcoming investor conferences in New York, NY.

• ViewRay Reports Second Quarter 2019 Results

  8/8/2019

  ViewRay, Inc. announced financial results for the second quarter ended June 30, 2019.

• ViewRay Announces Conference Call and Webcast of Second Quarter 2019 Financial Results to be Held After Market on August 8, 2019

  7/18/2019

  ViewRay, Inc. announced details relating to the release of its second quarter 2019 financial results.

• ViewRay Announces Appointment of Dr. Gail Wilensky to its Board of Directors

  7/16/2019

  ViewRay, Inc. announced the appointment of Dr. Gail Wilensky to its Board of Directors.

• Leading Medical Physics Meeting to Feature More than 40 Presentations on ViewRay's MRIdian MRI-Guided Radiotherapy

  7/10/2019

  Presentations Highlight MRIdian Clinical Experience with Real-Time On-Table Adaptive Radiotherapy at a Growing Number of Institutions Worldwide